715 related articles for article (PubMed ID: 28514624)
1. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM; Nicholls SJ; Riesmeyer JS; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Granger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Wolski K; Ruotolo G; Vangerow B; Weerakkody G; Goodman SG; Conde D; McGuire DK; Nicolau JC; Leiva-Pons JL; Pesant Y; Li W; Kandath D; Kouz S; Tahirkheli N; Mason D; Nissen SE;
N Engl J Med; 2017 May; 376(20):1933-1942. PubMed ID: 28514624
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
Nicholls SJ; Lincoff AM; Barter PJ; Brewer HB; Fox KA; Gibson CM; Grainger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Riesmeyer J; Vangerow B; Ruotolo G; Weerakkody GJ; Nissen SE
Am Heart J; 2015 Dec; 170(6):1061-9. PubMed ID: 26678626
[TBL] [Abstract][Full Text] [Related]
3. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
Menon V; Kumar A; Patel DR; St John J; Riesmeyer J; Weerakkody G; Ruotolo G; Wolski KE; McErlean E; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32179516
[TBL] [Abstract][Full Text] [Related]
4. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
5. ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
Nissen SE; Pillai SG; Nicholls SJ; Wolski K; Riesmeyer JS; Weerakkody GJ; Foster WM; McErlean E; Li L; Bhatnagar P; Ruotolo G; Lincoff AM
JAMA Cardiol; 2018 May; 3(5):401-408. PubMed ID: 29525816
[TBL] [Abstract][Full Text] [Related]
6. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
7. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
8. Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.
Kumar A; Patel DR; Brennan DM; Wolski KE; Lincoff AM; Ruotolo G; McErlean E; Weerakkody G; Riesmeyer JS; Nicholls SJ; Nissen SE; Menon V
J Am Heart Assoc; 2019 Dec; 8(23):e013790. PubMed ID: 31752637
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.
Teramoto T; Kiyosue A; Iimura T; Takita Y; Riesmeyer JS; Murakami M
Circ J; 2017 Oct; 81(11):1686-1692. PubMed ID: 28652529
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
[TBL] [Abstract][Full Text] [Related]
12. Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
[TBL] [Abstract][Full Text] [Related]
13. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
Eyvazian VA; Frishman WH
Cardiol Rev; 2017; 25(2):43-52. PubMed ID: 28099220
[TBL] [Abstract][Full Text] [Related]
14. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
; Bowman L; Hopewell JC; Chen F; Wallendszus K; Stevens W; Collins R; Wiviott SD; Cannon CP; Braunwald E; Sammons E; Landray MJ
N Engl J Med; 2017 Sep; 377(13):1217-1227. PubMed ID: 28847206
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
Curr Pharm Des; 2016; 22(5):595-608. PubMed ID: 26601964
[TBL] [Abstract][Full Text] [Related]
17. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
Teramoto T; Kiyosue A; Iimura T; Takita Y; Riesmeyer JS; Murakami M
Circ J; 2017 Dec; 82(1):183-191. PubMed ID: 28768921
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW; Karpov Y; Kastelein JJP; Koenig W; Lorenzatti A; Manga P; Masiukiewicz U; Miller M; Mosterd A; Murin J; Nicolau JC; Nissen S; Ponikowski P; Santos RD; Schwartz PF; Soran H; White H; Wright RS; Vrablik M; Yunis C; Shear CL; Tardif JC;
N Engl J Med; 2017 Apr; 376(16):1527-1539. PubMed ID: 28304242
[TBL] [Abstract][Full Text] [Related]
20. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.
Suico JG; Wang MD; Friedrich S; Cannady EA; Konkoy CS; Ruotolo G; Krueger KA
J Pharm Pharmacol; 2014 Nov; 66(11):1576-85. PubMed ID: 24961753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
